<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394975</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-036-Ⅲ-RCC</org_study_id>
    <nct_id>NCT04394975</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer</brief_title>
  <official_title>A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, controlled, multicenter, phase III trial to compare the
      efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a
      first-line therapy for advanced RCC. Eligible patients will be randomized 1:1 to receive the
      combination therapy of Toripalimab and axitinib or sunitinib monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 19, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS assessed by IRC per RECIST 1.1.</measure>
    <time_frame>3 years</time_frame>
    <description>To compare the progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST) 1.1 as assessed by independent review committee (IRC) in subjects treated with Toripalimab plus axitinib vesus sunitinib monotherapy as a first-line treatment for advanced RCC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by investigators per RECIST 1.1;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR, assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS assessed by investigators and IRC per RECIST 1.1, respectively;</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and grade of AEs and SAEs per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, incidence of ≥ grade 3 AE;</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and grade of AEs and SAEs related to study drugs per NCI-CTCAE version 5.0, AEs ≥ grade 3 related to the study drugs.</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation between biomarker (PD-L1) and the efficacy of Toripalimab</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib monotherapy. Participants receive sunitinib 50mg orally once daily for 4 weeks and then are off treatment for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Biological : Toripalimab Drug: Axitinib sunitinib</intervention_name>
    <description>Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet Drug: Sunitinib, oral capsule</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fully understand and be willing to provide written informed consent.

          2. Male or female with age ≥ 18 years and ≤80 years.

          3. Have received no prior systemic therapy for RCC, histologically confirmed diagnosis of
             unresectable, recurrent or metastatic RCC with clear cell component with or without
             sarcomatoid features.

          4. Having at least one measurable disease per RECIST 1.1. Lesions situated in a
             previously irradiated area are considered measurable if re-progression has been
             demonstrated.

          5. Provide archival tumor tissues or newly obtained biopsies if patients participate in
             the exploratory study.

          6. ECOG PS 0 or 1.

          7. Adequate function of vital organs:

             Bone marrow function (without blood or blood products transfusion, without
             hematopoietic stimulating factor or other medication to improve blood cell count
             within 2 days prior to first dose of study drug):

             Absolute neutrophil count (ANC) ≥ 1.5×10*9/L. Platelets ≥ 100×10*9/L. Hemoglobin ≥
             9.0g/dL or ≥ 5.6mmol/L.

             Renal function:

             Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 60mL/min for subjects with serum
             creatinine &gt;1.5×ULN.

             Hepatic function:

             Serum total bilirubin ≤1.5×ULN or total bilirubin levels &gt;1.5×ULN with direct
             bilirubin ≤ ULN.

             AST and ALT ≤2.5 × ULN, ≤5×ULN in those with hepatic metastasis.

             Endocrine function:

             Normal thyroid stimulating hormone, or abnormal TSH whilst normal FT3 and FT4.

             Coagulation function:

             International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, and activated
             partial thromboplastin time (aPTT) ≤1.5×ULN.

             Left ventricular ejection fraction (LVEF) ≥ LLN.

          8. Being willing and able to comply with scheduled visits, treatment plan, laboratory
             tests and other study procedures.

          9. Female subjects of childbearing potential must have a negative serum pregnancy test
             within 7 days prior to the first treatment dose. Female subjects of childbearing
             potential and male subjects whose partners are of childbearing potential must agree to
             use a highly effective methods of contraceptive throughout the study and for 180 days
             after the last dose of study therapy.

        Exclusion Criteria:

        Patients with any of the following conditions will not be included in the study:

          1. Prior anti-cancer immunotherapy, including (but not limited to) cytokines (IL-2,
             IFN-α, etc.) and antibodies (i.e., anti-PD-1, PD-L1 or CTLA-4 agents).

          2. Prior systemic anti-cancer therapy (e.g., VEGF/VEGFR or mTOR targeting agents,
             including (but not limited to) sunitinib, axitinib, sorafenib, pazopanib,
             cabozantinib, lenvatinib, bevacizumab or everolimus.

          3. Progression or recurrence during neoadjuvant/adjuvant therapy for renal cell cancer or
             within 12 months after the last dose treatment.

          4. Has participated or is currently participating in a trial of investigational agent
             within 4 weeks prior to the first dose of study treatment, unless observational
             (non-interventional) clinical study or follow-up period of interventional study. Had
             major surgery (judged by investigators) within 4 weeks prior to the first dose of
             study treatment or has not recovered from prior surgery.

          5. Has traditional Chinese medicine or Chinese patent medicine preparation with
             anti-cancer indication within 2 weeks prior to the first dose of study treatment.
             Requiring corticosteroids (Prednisone &gt;10 mg/day or equivalent analogue) or other
             immunosuppressive agents within 2 weeks prior to the first dose of study treatment.
             Patients without active autoimmune disease using inhaled prednisone &gt;10 mg/day will
             not be excluded from the study.

          6. Not recovered from the toxicity of prior anti-cancer therapy, i.e., not recovered to
             baseline, Grade 0-1 (NCI-CTCAE 5.0, except alopecia) or per inclusion/exclusion
             criteria in protocol. Under rational expectation, irreversible toxicities (e.g.,
             hearing loss) which will not be worsened by study treatments may be enrolled in the
             study.

          7. Has an additional malignancy that has progressed or required treatment within 5 years
             prior to randomization (basal cell carcinoma of the skin, squamous cell carcinoma of
             the skin, superficial bladder cancer, or carcinoma in situ such as breast cancer,
             cervical cancer or prostate cancer are acceptable if they have undergone potentially
             curative therapy ).

          8. Has a history of central nervous system (CNS) metastasis or CNS metastasis had been
             confirmed by radiological examination (MRI or CT) at baseline within 30 days prior to
             the first dose of study drug.

          9. Poorly controlled hypertension with single agent (systolic blood pressure ≥ 150mmHg
             and/or diastolic blood pressure ≥ 90mmHg).

         10. Presence of the following cardiovascular events within 6 months prior to
             randomization:

             a .Myocardial infarction b. Unstable angina pectoris c. Cardiac angioplasty or stent
             d. Coronary/peripheral artery bypass graft e.Grade III or IV congestive heart failure
             per New York Heart Association f. Cerebrovascular accident or transient ischemic
             attack

         11. QT interval (QTc) ≥ 480 msec corrected with heart rate (Bazett's formula);

         12. Has active hemorrhage or history of other significant hemorrhage episodes within 30
             days prior to randomization. Has hemoptysis within 6 weeks prior to randomization.

         13. Has deep vein thrombosis or pulmonary embolism within 6 months prior to randomization.

         14. Has clinically significant gastrointestinal (GI) abnormalities including:

               1. Malabsorption, total gastrectomy or any other condition that might affect the
                  absorption of orally taken medication.

               2. Active ulcer under treatment in the past 6 months;

               3. Active GI bleeding (e.g., hematemesis, hematochezia or melena) in the past 3
                  months, and without evidence of resolution documented by endoscopy or
                  colonoscopy.

               4. Intraluminal metastatic lesion with suspected hemorrhage, inflammatory bowel
                  disease, ulcerative colitis, GI perforation, or other GI conditions associated
                  with increased risk of perforation.

         15. Has a history of organ transplantation or required long-term treatment with
             corticosteroids. Hypothyroidism, hypoadrenalism or hypopituitarism that can be
             controlled only with hormone replacement therapy, type I diabetes, psoriasis or
             leucoderma not requiring systematic treatment.

         16. Has a history of or current (non-infective) pneumonia/ interstitial lung disease that
             required steroids.

         17. Has an active infection requiring systemic therapy. Has a known history of Human
             Immunodeficiency Virus (HIV) infection (HIV antibody positive), HBV or HCV infection
             (Patients with positive HBsAg or negative HBsAg, but positive HBcAb will be enrolled
             in the study when HBV DNA was tested in central laboratory and lower than ULN.
             Patients with a history of HCV infection may participate in the study if the result of
             HCV RNA test was negative during screening period).

         18. Has received a live virus vaccine within 30 days prior to randomization, including
             (but not limited to) mumps, rubella, measles, varicella/ herpes zoster (chicken pox),
             yellow fever, rabies, Bacille Calmette-Guérin (BCG) and typhoid vaccine. Inactivated
             virus vaccines are allowed.

         19. Has a history of hypersensitivity reaction, including (but not limited to) antibodies
             and TKIs.

         20. Known history of psychiatric disorders or drug abuse.

         21. Has evidence of inadequate wound healing.

         22. Has current use (within 7 days of randomization) or anticipated need for treatment
             drugs what are known strong CYP3A4/5 inhibitor and CYP3A4/5 inducer (including, but
             not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin and St.
             John's wort) or the drugs that are known with proarrhythmic potential (including, but
             not limited to, terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol
             and benazapril, etc.).

         23. Has a history or current evidence on any condition, therapy or laboratory abnormality
             that might confound the results of the study, interfere with subject's participation
             for the full duration of the study, or is not in the best interest of subject to
             participate, in the opinion of investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

